APTO 253 companion diagnostic
Latest Information Update: 11 Nov 2014
At a glance
- Originator Aptose Biosciences
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 29 Sep 2014 Phase-I clinical trials in Cancer (Diagnosis) in USA (unspecified route)